Skip to main content
. 2019 Mar 15;14(3):e0209392. doi: 10.1371/journal.pone.0209392

Fig 2. FND-4b activated AMPKα and its downstream signaling pathways in a dose-dependent manner in breast cancer.

Fig 2

Equal numbers of MCF-7, T-47D, MDA-MB-231, HCC-1806 or breast cancer stem cells were treated with fresh medium that contained different FND-4b concentrations (0, 1, 2.5, 5, 10, and 20 μM) for 24 h. Western blot analysis was then performed for phosphorylated and total forms of AMPKα, ACC, and S6 as well as cyclin D1 and cleaved PARP. Beta-actin was used as the loading control. Treatment of the HCC-1806 cell line was repeated to confirm the spike in AMPKα activation at the 5 μM dosage with subsequent decreases at higher concentrations.